SunTrust Robinson analyst John Boris initiated coverage with a Buy rating on Amneal Pharmaceuticals Inc (AMRX) today and set a price target of $16. The company’s shares closed yesterday at $14.41.
According to TipRanks.com, Boris is a 5-star analyst with an average return of 15.8% and a 60.0% success rate. Boris covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Mallinckrodt, and Amarin.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amneal Pharmaceuticals Inc with a $23.50 average price target.
See today’s analyst top recommended stocks >>
Based on Amneal Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.77 million. In comparison, last year the company had a GAAP net loss of $301 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments.
